• Applications & Products
  • Media Formulation
  • About InVitria
  • Contact Us
  • Terms
  • Privacy
  • Sitemap
Performance. Defined.
  • 1-800-916-8311 or Email Us
  • iconMy Account
  • iconView Cart
  • Applications & Products
    • Applications
      • Gene Therapy
      • Cell Therapy
      • T-Cell Immunotherapy
      • Vaccine Production
      • Antibody Production
      • Final Formulation
      • Food Science
    • Product Types
      • Blood-Free Cell Culture Media
      • Cell Culture Components
      • Insulin-Transferrin Supplements
      • Recombinant Albumin
      • Recombinant Transferrin
      • Recombinant Lysozyme
    • Products
      • Cellastim S – Recombinant human albumin
      • Exbumin® – Recombinant human albumin excipient
      • Optibumin – Recombinant human albumin
      • Optiferrin – Recombinant human transferrin
      • Lacromin – Recombinant human holo lactoferrin
      • ITS AF – Blood-free cell culture media supplement
      • ITSE + A – Blood-free cell culture media supplement
      • ITSE Animal-Free® – Blood-free cell culture media supplement
      • Lysobac – Recombinant human lysozyme
      • Leukemia Inhibitory Factor
      • OptiPEAK® HEK293t
      • OptiPEAK® T Lymphocyte XPR
      • OptiVERO®
  • Media Formulation
  • About InVitria
  • News & Blog
  • Contact Us
  • Applications
  • Products
  • Contact Us
  • Home
  • Chemically Defined iCELLis® Bioreactor-Based Viral Vector Manufacturing – Application of Aber Biomass Probes to Inform Transfection Timing

Chemically Defined iCELLis® Bioreactor-Based Viral Vector Manufacturing – Application of Aber Biomass Probes to Inform Transfection Timing

Published on 10 October 2021

Application of Aber’s FUTURA Biomass Probes to Inform Transfection and Cell Lysis in iCELLis Bioreactor-Based AAV Manufacturing

 

InVitria: Atherly Pennybaker, Media Formulation and Product Applications Specialist, Randy Alfano, PhD, VP Product Development, Sofia Pezoa, PhD, Cell Culture Scientist

Pall: Todd Lundeen, Andrew Laskowski

Abstract

Utilization of classical adherent formats in large scale viral vector manufacturing can have significant setbacks due to the lack of scalability of production vessels typically used at small scale. The iCELLis fixed bed bioreactor has emerged as an enabling technology to efficiently scale adherent-based processes in a controlled and highly integrated environment. This technology has been developed for the clinical manufacture of lentiviral and adeno-associated vectors with commercially viable yields. Aber’s FUTURA Biomass probes, which induce polarization of cells and measures the resulting capacitance of the medium in pF/cm, can be employed with the iCELLis bioreactor to provide direct online information on cell biomass during a viral vector production run. Routine utilization of these probes can provide invaluable online information regarding cell growth and health, control of feed/perfusion rate, and the identification of optimal time for transfection or harvest. Here, we utilized Aber’s FUTURA Biomass probes in iCELLis bioreactor runs to produce an AAV-2 GFP vector in OptiPEAK HEK293t chemically defined media, using different feeding strategies and harvest protocols of the bioreactor. Data obtained from the biomass probes are correlated with overall functional vector titer to identify ideal capacitance trends that are predictive of bioreactor productivity. Taken together, these data suggest the Aber’s FUTURA Biomass probes can be used to identify ideal capacitance ranges to commence major unit operations of the manufacturing process to maximize vector yields.

Objective

  • To demonstrate that the Aber Futura biomass probe can be used to accurately determine optimal transfection cell density, as cell density at the time of transfection (TF) is a major determinant of overall vector productivity:
    • Over/under confluent cultures can yield poor productivity
    • Nuclei-based counting is time consuming, and reproducibility is limited
  • To demonstrate practical application of biomass probes to maximize vector production and reproducibility in Pall’s iCELLis bioreactor

iCELLis Bioreactor Background

  • Provides clinical and commercial manufacturing of viral vectors and vaccines from adherent cells by utilizing:
    • Cell substrate composed of medical grade, uncoated, uncharged polyethylene teraphalate (PET) carriers
    • A closed system with reduced footprint and minimal aseptic handling
  • Controls pH and dissolved oxygen (DO) through a falling film that provides:
    • High gas transfer rates due to large surface area and thin film mass transfer, no sparging required
    • No cell shear due to rising bubbles or bubble burst
  • Exhibits bench- and commercial-size scalability by maintaining fixed bed height and carrier compaction

Aber Futura Biomass Probe Background

Pall’s iCELLis 500+
bioreactor
  • Provides continuous, online, direct measurements of biomass by inducing polarization of viable cells and measuring the resulting capacitance in pF/cm
  • Allows measurements of cell biomass during a viral vector production run through integration into the iCELLis bioreactor
  • Provides invaluable real-time information regarding cell growth and health, elucidating optimal times for operations such as:
    • Control of feed/perfusion rate
    • Transfection
    • Harvest

InVitria OptiPEAK® HEK293t Serum-Free Media (SFM) Background

  • Chemically defined media that is optimized specifically for adherent HEK-based adeno-associated virus (AAV) and lentivirus (LV) vector production in the iCELLis bioreactor:
    • Reduces foaming and other technical challenges in bioreactors
    • Provides high performance in culture, both for cell expansion and viral titer
  • Developed to circumvent the high variability and cost found in classical serum supplemented media for virus production:
    • Creates more consistent cell growth and more dependable manufacturing yield by reducing donor-dependent variation
    • Eliminates concerns about the global supply chain and limitations on availability of human and bovine serum
  • Utilizes a recombinant human transferrin and albumin from a large-scale non-mammalian expression platform and therefore does not incorporate any human or blood-derived components:
    • Prevents the introduction of undesirable viral RNA and DNA, prion proteins, undefined antigenic molecules, and human or animal cytokines and hormones
    • Uses blood-free components to eliminate adventitious pathogenic agents that can be found in blood-derived products

Methods

  • HEK293 (AAV) or HEK293T (LV) cells were expanded in flatware either in OptiPEAK HEK293t media or DMEM+10% fetal bovine serum (FBS) as seed stock for 5,300 cm2 iCELLis Nano bioreactors. Cells were media-adapted for at least three passages prior to seeding in the bioreactors. Key bioreactor parameters are described in Table 1
  • Capacitance readings from the biomass probes were converted to cells/cm2 as determined by the formula: Nuclei count (cells/cm2) = m3 x capacitance where m3 = 928.47 as described previously1
  • PEI-mediated triple transfections of either AAV-2 GFP or LV GFP were performed at specific capacitance measurements
  • Production times for each vector were 72 hours from transfection to harvest
Table 1
iCELLis bioreactor set points for OptiPEAK HEK293t media

 

Results

To determine optimal transfection densities in the iCELLis bioreactor with OptiPEAK HEK293t media, transfections using AAV, and LV were done at different cell densities according to the biomass probes. Vector yield was plotted as a function of the highest titers achieved in this series of experiments (Figure 1). Transfections were performed anywhere between day two and day five post-inoculation of the bioreactor.

T-Flask Transfections with LV (HEK293T)

iCELLis bioreactor titer data suggested that lower transfection cell densities yielded higher vector titer for both AAV and LV. To correlate these observations made in the iCELLis bioreactor measured by the biomass probe to T-flasks measured by traditional cell counts, HEK293T cells were plated at different cell densities (Figure 2) in T-75 flasks and then transfected 16 hours later. Supernatants were analyzed for functional LV titers in both DMEM+FBS and OptiPEAK HEK293t media. Optimal cell density at the time of transfection was determined to be 75,000 cells/cm2 for both media, aligning with previous iCELLis bioreactor results.

Collectively, the data suggested cell densities of 70,000 cells/cm2 produced the highest titer of vector in the iCELLis bioreactor. Three serial runs of iCELLis Nano bioreactors using OptiPEAK HEK293t media were performed using the biomass probes (Figure 3). Bioreactors were transfected (arrow) when capacitance reached 74-80 pF/cm, corresponding to 68,000 to 74,000 cells/cm2. Transfections were typically two days post inoculation. Total volume of virus-containing supernatant harvested from each bioreactor was 900 mL.

Average yield was determined to be 1.13 x 107 ±0.27×107 IFU/mL. The coefficient of variation was found to be 24% between runs.

Transfection results figures

 

Conclusion

  • Biomass probes can accurately assess cell growth in the iCELLis bioreactor
  • Optimal transfection cell density for AAV and LV production was determined to be approximately 70,000 cells/cm2 in the iCELLis bioreactor using OptiPEAK HEK293t media
  • Using capacitance to define the time of transfection led to high productivity of LV vector with acceptable reproducibility in chemically defined media
  • Current work is focused on applying the same principle in iCELLis bioreactor-based AAV manufacturing
View PDF Here

Footnotes

InVitria: +1 800 916 8311 (USA) • Email us at: https://invitria.com/contact-us/ or info@invitria.com • Web: www.invitria.com

Pall Corporation: +1 800 717 7255 (USA) • +41 (0)26 350 53 00 (Europe) • +65 6389 6500 (Asia/Pacific) • Email us at: www.pall.com/contact • Web: www.pall.com/biotech

Start New Search

Quick Search Links

Application:

Antibody Production

Cell Therapy

Final Formulation

Food Science

Gene Therapy

T-Cell Immunotherapy

Vaccine Production

Product Category:

Cell Culture Supplements

Albumin

Cell Culture Media

Lactoferrin

LIF

Lysozyme

Single Components

Transferrin

Product:

Cellastim S® – Recombinant human albumin

Exbumin® – Recombinant human albumin excipient

ITS AF™ – Blood-free cell culture media supplement

ITSE + A™ – Blood-free cell culture media supplement

ITSE Animal-Free® – Blood-free cell culture media supplement

Lacromin® – Recombinant human holo-lactoferrin

Leukemia Inhibitory Factor

Lysobac® – Recombinant human lysozyme

Optibumin® – Recombinant human albumin

Optiferrin® – Recombinant human transferrin

OptiPEAK® HEK293t

OptiPEAK® T Lymphocyte XPR

OptiVERO®

Document Type:

Application Notes

Blog

Interviews

Journal Articles (DOI Links)

News

Posters

Product Brochures

Product Specifications

SDS

Use Guidelines

Webinar

White Papers

Cell Line:

B Lymphocyte

CHO

ESC

HEK293

Hematopoetic Stem Cells

Hybridoma

iPSC

Mesenchymal Stem Cells

Natural Killer Cells

Neural Stem Cells

T Lymphocyte

VERO

  • 2718 Industrial Drive • Junction City, KS 66441
  • 800-916-8311
  • © 2022 InVitria

    • Terms
    • Privacy
    • Sitemap